<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017428</url>
  </required_header>
  <id_info>
    <org_study_id>1725738</org_study_id>
    <nct_id>NCT05017428</nct_id>
  </id_info>
  <brief_title>Absorption and Digestion Kinetics of Human Metabolites</brief_title>
  <official_title>Absorption and Digestion Kinetics of Human Metabolites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to evaluate the effects oral supplementation with four&#xD;
      human metabolites (spermidine, nicotinamide, palmitoylethanolamide (PEA), and&#xD;
      oleoylethanolamide(OEA)) at varying doses on the circulating blood levels of these&#xD;
      metabolites as well as their immediate effects on plasma functionality and postprandial&#xD;
      inflammation. 5 young healthy subjects will participate in a four armed study consisting of a&#xD;
      Placebo arm and a Low, Medium, and High Dose arm. Subjects will be given a standardized&#xD;
      breakfast along with supplementation with either an escalating dose (Low: 1x, Medium: 2x,&#xD;
      High: 3x) of a combination of spermidine, nicotinamide, PEA and OEA or a placebo control and&#xD;
      a time course of their blood plasma will be collected after supplementation. Plasma samples&#xD;
      will be assessed for their concentration of spermidine, nicotinamide, PEA, and OEA as well as&#xD;
      their experimental and clinical functionalities including their anti-inflammatory,&#xD;
      antioxidant, and cholesterol efflux abilities on primary human macrophage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Actual">July 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will take a supplement containing 4 metabolites at escalating doses compared with placebo after a standardized meal and their blood will be drawn at mutliple points throughout a postprandial time course to evaluate markers of inflammation, circulating levels of each metabolite, and plasma functionalities.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating Plasma Levels of Metabolites</measure>
    <time_frame>1, 2, and 4 hours after ingestion</time_frame>
    <description>Quantitative plasma concentrations of spermidine, nicotinamide, pamitoylethanolamide, and oleoylethanolamide (in nmol/L).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-inflammatory capacity of plasma</measure>
    <time_frame>1, 2, and 4 hours after ingestion</time_frame>
    <description>Ex vivo assessment of the effects of subject plasma on the secretion of pro-inflammatory cytokine TNF-alpha (pg/mL) by primary human macrophage</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Postprandial Inflammation</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Low Dose arm provides subjects with supplementation with 5mg of spermidine (in the form of 5g of a 0.1% spermidine wheat germ extract), 500mg of nicotinamide, 400mg of palmitoylethanolamide, and 200mg of oleoylethanolamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Medium Dose arm provides subjects with supplementation with 10mg of spermidine (in the form of 10g of a 0.1% spermidine wheat germ extract), 750mg of nicotinamide, 800mg of palmitoylethanolamide, and 400mg of oleoylethanolamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Low Dose arm provides subjects with supplementation with 15mg of spermidine (in the form of 15g of a 0.1% spermidine wheat germ extract), 1000mg of nicotinamide, 1200mg of palmitoylethanolamide, and 600mg of oleoylethanolamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this arm the participants are given supplementation with a placebo control consisting of 15g of wheat flour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Spermidine</intervention_name>
    <description>Spermidine in the form of a 0.1% spermidine wheat germ extract</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Medium Dose</arm_group_label>
    <other_name>Primeadine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide</intervention_name>
    <description>Nicotinamide given as niacinamide</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Medium Dose</arm_group_label>
    <other_name>Jarrow Niacinamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PEA</intervention_name>
    <description>Palmitoylethanolamide given at 98% purity</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Medium Dose</arm_group_label>
    <other_name>Nootropics Depot PEA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>OEA</intervention_name>
    <description>Oleoylehtanolamide given at 90% purity</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Medium Dose</arm_group_label>
    <other_name>Riduzone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Wheat Flour</intervention_name>
    <description>Wheat flour given as a placebo control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 20-40 years old to constitute a young study population&#xD;
&#xD;
          -  BMI: 19-27 kg/m2 to constitute a normal/healthy weight population&#xD;
&#xD;
          -  Weight: 133lbs or more&#xD;
&#xD;
          -  Subjects must be willing and able to consume a standardized breakfast bar containing&#xD;
             cashews and dates (Larabar).&#xD;
&#xD;
          -  Subjects must be willing to consume oral dietary supplement versions of spermidine,&#xD;
             1-methlynicotinamide, palmitoylethanolamide, and oleoylethanolamide.&#xD;
&#xD;
          -  Subjects must be willing and able to undergo blood draws at the UC Davis Ragle&#xD;
             Nutrition Center at 0, 1, 2, and 4 hours after supplementation with spermidine,&#xD;
             niacinamide, palmitoylethanolamide, and oleoylethanolamide.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Documented chronic diseases including diabetes, thyroid disease, metabolic syndrome,&#xD;
             cancer, autoimmune diseases, or previous cardiovascular events&#xD;
&#xD;
          -  Any inflammatory bowel disease including IBS, Crohn's Disease, Celiac Disease&#xD;
&#xD;
          -  Any allergy or sensitivity to wheat, gluten, or soy products&#xD;
&#xD;
          -  Consumption of &gt;1 alcoholic drink/day&#xD;
&#xD;
          -  Current consumption of any probiotic, prebiotic, or dietary supplements&#xD;
&#xD;
          -  Extreme dietary or exercise patterns&#xD;
&#xD;
          -  Recent weight fluctuations (greater than 10% in the last six months)&#xD;
&#xD;
          -  Regular use of over-the-counter allergy or pain medications (&gt;1/week)&#xD;
&#xD;
          -  Taking prescription lipid medications (e.g. statins) or other supplements known to&#xD;
             alter lipoprotein metabolism such as isoflavones.&#xD;
&#xD;
          -  Use of any form of hormonal birth control including oral contraception pills, hormonal&#xD;
             IUDs or rings, or hormonal birth control patches&#xD;
&#xD;
          -  Illness such as flu or cold of any kind within the last two weeks&#xD;
&#xD;
          -  Allergy to components of standardized breakfast bar (cashew/dates)&#xD;
&#xD;
          -  Changes to any of the above during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participation in the study will be restricted to males. Women will be excluded from the study as the study protocol includes multiple study arms to be completed within a 1 month timeframe. Biological variations caused by the menstrual cycle throughout a single month may cause week to week variability in the absorption, digestion, and metabolism of our metabolites of interest that cannot be controlled for in this small pilot study.</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Angela Zivkovic, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

